SCHEMBL25865897

SCHEMBL25865897

N#CC1C=C(c2c[nH]c3ncccc23)CNC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.68
HTR2C P28335 1/20 0.68
HTR2B P41595 1/20 0.68
LRRK2 Q5S007 1/20 0.48
TGFBR1 P36897 3/20 0.44
IKBKE Q14164 2/20 0.44
PDPK1 O15530 2/20 0.44
TBK1 Q9UHD2 2/20 0.41
RPS6KA5 O75582 1/20 0.41
CDC7 O00311 5/20 0.41
JAK3 P52333 2/20 0.40
CDK2 P24941 3/20 0.40
CDK9 P50750 3/20 0.40
CCNT1 O60563 2/20 0.40
MAP4K4 O95819 2/20 0.40
PIM1 P11309 2/20 0.40
PRKACA P17612 2/20 0.40
GSK3B P49841 2/20 0.40
HIPK2 Q9H2X6 2/20 0.40
CLK4 Q9HAZ1 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30532644 0.81 HTR2A (1.00) HTR2AHTR2CHTR2BLRRK2TGFBR1
SCHEMBL26646622 0.81 HTR2A (1.00) HTR2AHTR2CHTR2BLRRK2TGFBR1
SCHEMBL26646654 0.81 HTR2A (1.00) HTR2AHTR2CHTR2BLRRK2TGFBR1
SCHEMBL30532650 0.81 HTR2A (1.00) HTR2AHTR2CHTR2BLRRK2TGFBR1
SCHEMBL30509688 0.81 HTR2A (1.00) HTR2AHTR2CHTR2BLRRK2TGFBR1
SCHEMBL25429922 0.81 HTR2A (1.00) HTR2AHTR2CHTR2BLRRK2TGFBR1
SCHEMBL30509693 0.78 HTR2A (0.68) HTR2AHTR2CHTR2BTGFBR1IKBKE
SCHEMBL25865698 0.78 HTR2A (0.68) HTR2AHTR2CHTR2BTGFBR1IKBKE
SCHEMBL25865894 0.78 HTR2A (0.72) HTR2AHTR2CHTR2BLRRK2TGFBR1
SCHEMBL30509692 0.78 HTR2A (0.49) HTR2AHTR2CHTR2BLRRK2TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4466266-B1 FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS TRANSNEURAL THERAPEUTICS INC (US) 2026-04-08 EP disclosed
US-12486268-B2 Fused heterocycles as 5-HT2A receptor agonists Transneural Therapeutics, Inc. (US) 2025-12-02 US disclosed
US-12459944-B2 Fused heterocycles as 5-HT2A receptor agonists Transneural Therapeutics, Inc. (US) 2025-11-04 US disclosed
US-20250243199-A1 FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS Transneural Therapeutics, Inc. (US) 2025-07-31 US disclosed
US-20240425503-A1 FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS Transneural Therapeutics, Inc. 2024-12-26 US disclosed
WO-2023141225-A1 FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS ONSERO THERAPEUTICS INC. (US) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12459944-B2 Fused heterocycles as 5-HT2A receptor agonists HTR2A, HTR2C, HTR5A HTR2A 1/4885HTR2C 2/4885HTR2B 6/4885
US-20250243199-A1 FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS HTR2A, HTR2C, HTR5A HTR2A 1/4885HTR2C 2/4885HTR2B 6/4885
US-20240425503-A1 FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS HTR2A, HTR2C, HTR1A HTR2A 1/4885HTR2C 2/4885HTR2B 6/4885
US-12486268-B2 Fused heterocycles as 5-HT2A receptor agonists HTR2A, HTR2C, HTR5A HTR2A 1/4885HTR2C 2/4885HTR2B 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.